TY - JOUR
T1 - Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease
T2 - A cohort study
AU - Vidula, Himabindu
AU - Tian, Lu
AU - Liu, Kiang
AU - Criqui, Michael H.
AU - Ferrucci, Luigi
AU - Pearce, William H.
AU - Greenland, Philip
AU - Green, David
AU - Tan, Jin
AU - Garside, Daniel B.
AU - Guralnik, Jack
AU - Ridker, Paul M.
AU - Rifai, Nader
AU - McDermott, Mary M.
PY - 2008/1/15
Y1 - 2008/1/15
N2 - Background: Traditional atherosclerotic risk factors predict long-term cardiovascular disease events but are poor predictors of near-term events. Objective: To determine whether elevated levels of D-dimer and biomarkers of inflammation were more closely associated with near-term than long-term mortality in patients with lower-extremity peripheral arterial disease (PAD) and whether greater increases in biomarker levels were associated with higher mortality rates during the first year after the increase than during later years. Design: Prospective cohort study with a mean follow-up of 3.4 years. Setting: Academic medical center. Patients: 377 men and women with PAD. Measurements: Mortality within 1 year after biomarker measurement, 1 to 2 years after biomarker measurement, and 2 to 3 years after biomarker measurement. Cox regression analyses were used to evaluate associations of biomarkers levels and changes in biomarkers with cardiovascular and all-cause mortality. Hazard ratios were calculated for each 1-unit increase in log1.5(biomarker level). Analyses were adjusted for age, sex, race, comorbid conditions, ankle-brachial index, and other confounders. Results: Seventy-six patients (20%) died during follow-up. Higher levels of D-dimer, C-reactive protein, and serum amyloid A were associated with higher all-cause mortality among patients who died within 1 year after biomarker measurement (hazard ratio, 1.20 [95% CI, 1.08 to 1.33], 1.13 [CI, 1.05 to 1.21], and 1.12 [CI, 1.04 to 1.20], respectively; P < 0.001, P < 0.001, and P = 0.003) and among patients who died 1 to 2 years after biomarker measurement (hazard ratio, 1.14 [CI, 1.02 to 1.27], 1.15 [CI, 1.06 to 1.24], and 1.13 [CI, 1.04 to 1.24]; P = 0.022, P = 0.001, and P = 0.005]). However, higher levels of each biomarker were not associated with all-cause mortality for deaths occurring 2 to 3 years after biomarker measurement. Similar results were observed for cardiovascular mortality. Greater increases in each biomarker were associated with higher all-cause and cardiovascular mortality during the following year. Limitation: The small number of deaths limited the statistical power of the analyses. Conclusion: Among persons with PAD, circulating levels of D-dimer and inflammatory markers are higher in the 1 to 2 years before death than in periods more remote from death. Increasing levels of D-dimer and inflammatory biomarkers are independently associated with higher mortality in persons with PAD.
AB - Background: Traditional atherosclerotic risk factors predict long-term cardiovascular disease events but are poor predictors of near-term events. Objective: To determine whether elevated levels of D-dimer and biomarkers of inflammation were more closely associated with near-term than long-term mortality in patients with lower-extremity peripheral arterial disease (PAD) and whether greater increases in biomarker levels were associated with higher mortality rates during the first year after the increase than during later years. Design: Prospective cohort study with a mean follow-up of 3.4 years. Setting: Academic medical center. Patients: 377 men and women with PAD. Measurements: Mortality within 1 year after biomarker measurement, 1 to 2 years after biomarker measurement, and 2 to 3 years after biomarker measurement. Cox regression analyses were used to evaluate associations of biomarkers levels and changes in biomarkers with cardiovascular and all-cause mortality. Hazard ratios were calculated for each 1-unit increase in log1.5(biomarker level). Analyses were adjusted for age, sex, race, comorbid conditions, ankle-brachial index, and other confounders. Results: Seventy-six patients (20%) died during follow-up. Higher levels of D-dimer, C-reactive protein, and serum amyloid A were associated with higher all-cause mortality among patients who died within 1 year after biomarker measurement (hazard ratio, 1.20 [95% CI, 1.08 to 1.33], 1.13 [CI, 1.05 to 1.21], and 1.12 [CI, 1.04 to 1.20], respectively; P < 0.001, P < 0.001, and P = 0.003) and among patients who died 1 to 2 years after biomarker measurement (hazard ratio, 1.14 [CI, 1.02 to 1.27], 1.15 [CI, 1.06 to 1.24], and 1.13 [CI, 1.04 to 1.24]; P = 0.022, P = 0.001, and P = 0.005]). However, higher levels of each biomarker were not associated with all-cause mortality for deaths occurring 2 to 3 years after biomarker measurement. Similar results were observed for cardiovascular mortality. Greater increases in each biomarker were associated with higher all-cause and cardiovascular mortality during the following year. Limitation: The small number of deaths limited the statistical power of the analyses. Conclusion: Among persons with PAD, circulating levels of D-dimer and inflammatory markers are higher in the 1 to 2 years before death than in periods more remote from death. Increasing levels of D-dimer and inflammatory biomarkers are independently associated with higher mortality in persons with PAD.
UR - http://www.scopus.com/inward/record.url?scp=38749139523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38749139523&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-148-2-200801150-00003
DO - 10.7326/0003-4819-148-2-200801150-00003
M3 - Article
C2 - 18195333
AN - SCOPUS:38749139523
SN - 0003-4819
VL - 148
SP - 85
EP - 93
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 2
ER -